ArticleMolecular immunology2007
Cellular uptake followed by class I MHC presentation of some exogenous peptides contributes to T cell stimulatory capacity.
Article in Molecular immunology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Bystander responses impact accurate detection of murine and human antigen-specific CD8 T cells.The Journal of clinical investigation · 2019Article
- Predicting lymph node output efficiency using systems biology.Journal of theoretical biology · 2013Article
- Promiscuous binding of extracellular peptides to cell surface class I MHC protein.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- Opposite effects of endogenous peptide-MHC class I on T cell activity in the presence and absence of CD8.Journal of immunology (Baltimore, Md. : 1950) · 2011Article
- Characterizing the dynamics of CD4+ T cell priming within a lymph node.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
- Different strategies adopted by K(b) and L(d) to generate T cell specificity directed against their respective bound peptides.The Journal of biological chemistry · 2009Article
- Engineering the binding properties of the T cell receptor:peptide:MHC ternary complex that governs T cell activity.Molecular immunology · 2009Article
- The impact of TCR-binding properties and antigen presentation format on T cell responsiveness.Journal of immunology (Baltimore, Md. : 1950) · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The T cell stimulatory activity of peptides is known to be associated with the cell surface stability and lifetime of the peptide-MHC (pepMHC) complex. In this report, soluble high-affinity T cell receptors (TCRs) that are specific for pepMHC complexes recognized by the mouse CD8+ clone 2C were used to monitor the cell surface lifetimes of synthetic agonist peptides. In the 2C system, L(d)-binding peptide p2Ca (LSPFPFDL) has up to 10,000-fold lower activity than peptide QL9 (QLSPFPFDL) even though the 2C TCR binds to p2Ca-L(d) and QL9-L(d) complexes with similar affinities. Unexpectedly, p2Ca-L(d) complexes were found to have a longer cell surface lifetime than QL9-L(d) complexes. However, the strong agonist activity of QL9 correlated with its ability to participate in efficient intracellular delivery followed by cell surface expression of the peptide, resulting in high and persistent surface levels of QL9-L(d). The ability of target cells to take up and present QL9 was observed with TAP-deficient cells and TAP-positive cells, including dendritic cells. The process was brefeldin A-sensitive, indicating a requirement for transport of the pepMHC through the ER and/or golgi. Thus, strong T cell stimulatory activity of some pepMHC complexes can be accomplished not only through long cell surface lifetimes of the ligand, but through a mechanism that leads to delayed presentation of the exogenous antigen after intracellular uptake.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.